Today’s Short Interest: Will Caladrius Biosciences Incorporated (NASDAQ:CLBS) Run Out of Steam Soon? Short Interest Is Down

November 29, 2016 - By Peter Erickson   ·   0 Comments

Today's Short Interest: Will Caladrius Biosciences Incorporated (NASDAQ:CLBS) Run Out of Steam Soon? Short Interest Is Down

The stock of Caladrius Biosciences Incorporated (NASDAQ:CLBS) registered a decrease of 37.85% in short interest. CLBS’s total short interest was 55,500 shares in November as published by FINRA. Its down 37.85% from 89,300 shares, reported previously. With 17,300 shares average volume, it will take short sellers 3 days to cover their CLBS’s short positions. About 8,852 shares traded hands. Caladrius Biosciences Inc (NASDAQ:CLBS) has declined 42.46% since April 26, 2016 and is downtrending. It has underperformed by 47.72% the S&P500.

Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company , provides development and manufacturing services to the cell therapy industry (which includes cell gene therapy). The company has a market cap of $31.35 million. PCT specializes in cell and cell gene therapies. It currently has negative earnings. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development.

Caladrius Biosciences Inc (NASDAQ:CLBS) Ratings Coverage

Out of 4 analysts covering Caladrius Biosciences (NASDAQ:CLBS), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. Caladrius Biosciences has been the topic of 7 analyst reports since August 7, 2015 according to StockzIntelligence Inc. On Tuesday, December 22 the stock rating was maintained by Maxim Group with “Buy”. Chardan Capital Markets initiated Caladrius Biosciences Inc (NASDAQ:CLBS) rating on Tuesday, August 23. Chardan Capital Markets has “Buy” rating and $6.50 price target. H.C. Wainwright downgraded the shares of CLBS in a report on Friday, January 8 to “Neutral” rating. The firm earned “Buy” rating on Friday, April 29 by H.C. Wainwright. The firm earned “Hold” rating on Friday, January 8 by Benchmark. The rating was downgraded by Benchmark to “” on Friday, August 7. The stock has “Hold” rating given by Maxim Group on Thursday, January 7.

CLBS Company Profile

Caladrius Biosciences, Inc., formerly NeoStem, Inc., incorporated on October 18, 1980, through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell gene therapy). PCT specializes in cell and cell gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation.

More notable recent Caladrius Biosciences Inc (NASDAQ:CLBS) news were published by: Marketwatch.com which released: “Caladrius Biosciences Inc.” on June 08, 2015, also Quotes.Wsj.com with their article: “News Caladrius Biosciences Inc.CLBS” published on June 09, 2015, Globenewswire.com published: “Caladrius Biosciences, Inc. Enters Into Agreements To Raise $25 Million in …” on September 15, 2016. More interesting news about Caladrius Biosciences Inc (NASDAQ:CLBS) were released by: Globenewswire.com and their article: “Caladrius Biosciences, Inc. Finalizes Corporate Name Change From NeoStem, Inc.” published on June 08, 2015 as well as Globenewswire.com‘s news article titled: “Caladrius Biosciences Subsidiary, PCT, Earns FACT Re-Accreditation for its …” with publication date: November 22, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Peter Erickson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>